Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis

Michael P Habib, Layne O. Gentry, Guillermo Rodriguez-Gomez, William Morowitz, Elaine Polak, Jena K. Rae, Nancy S. Morgan, R. Rex Williams

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

This prospective, multicenter randomized trial compared the safety and efficacy of 5-7 of therapy with oral levofloxacin (500 mg qd) with 7-10 days of therapy with cefaclor (250 mg tid) in the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB). One hundred ninety- two patients were evaluable of microbiologic efficacy. The overall bacteriologic eradication rates by pathogen were 94% and 87% for levoflaxacin and cefaclor, respectively. Levofloxacin eradicated 100% of Haemophilus influenzae, 95% of Moraxella catarrhalis, and 90% of Streptococcus pneumoniae organisms vs. 71%, 100%, and 86%, respectively, for cefaclor. Clinical success was observed in 92% of the patients in both groups. Drug-related adverse events were reported in 7% and 5% of patients, respectively, with gastrointestinal adverse events being the most common. These results indicate that once a day dosing of levofloxacin (500 mgg) is as effective and well tolerated as three-times-per-day dosing of cefaclor (250 mgg) in the treatment of patients with ABECB.

Original languageEnglish (US)
Pages (from-to)101-109
Number of pages9
JournalInfectious Diseases in Clinical Practice
Volume7
Issue number2
StatePublished - Feb 1998

Fingerprint

Cefaclor
Levofloxacin
Chronic Bronchitis
Multicenter Studies
Safety
Therapeutics
Moraxella (Branhamella) catarrhalis
Haemophilus influenzae
Streptococcus pneumoniae
Drug-Related Side Effects and Adverse Reactions

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. / Habib, Michael P; Gentry, Layne O.; Rodriguez-Gomez, Guillermo; Morowitz, William; Polak, Elaine; Rae, Jena K.; Morgan, Nancy S.; Williams, R. Rex.

In: Infectious Diseases in Clinical Practice, Vol. 7, No. 2, 02.1998, p. 101-109.

Research output: Contribution to journalArticle

Habib, Michael P ; Gentry, Layne O. ; Rodriguez-Gomez, Guillermo ; Morowitz, William ; Polak, Elaine ; Rae, Jena K. ; Morgan, Nancy S. ; Williams, R. Rex. / Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. In: Infectious Diseases in Clinical Practice. 1998 ; Vol. 7, No. 2. pp. 101-109.
@article{afe0d9c477864d938f2c7d03b2bfc232,
title = "Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis",
abstract = "This prospective, multicenter randomized trial compared the safety and efficacy of 5-7 of therapy with oral levofloxacin (500 mg qd) with 7-10 days of therapy with cefaclor (250 mg tid) in the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB). One hundred ninety- two patients were evaluable of microbiologic efficacy. The overall bacteriologic eradication rates by pathogen were 94{\%} and 87{\%} for levoflaxacin and cefaclor, respectively. Levofloxacin eradicated 100{\%} of Haemophilus influenzae, 95{\%} of Moraxella catarrhalis, and 90{\%} of Streptococcus pneumoniae organisms vs. 71{\%}, 100{\%}, and 86{\%}, respectively, for cefaclor. Clinical success was observed in 92{\%} of the patients in both groups. Drug-related adverse events were reported in 7{\%} and 5{\%} of patients, respectively, with gastrointestinal adverse events being the most common. These results indicate that once a day dosing of levofloxacin (500 mgg) is as effective and well tolerated as three-times-per-day dosing of cefaclor (250 mgg) in the treatment of patients with ABECB.",
author = "Habib, {Michael P} and Gentry, {Layne O.} and Guillermo Rodriguez-Gomez and William Morowitz and Elaine Polak and Rae, {Jena K.} and Morgan, {Nancy S.} and Williams, {R. Rex}",
year = "1998",
month = "2",
language = "English (US)",
volume = "7",
pages = "101--109",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis

AU - Habib, Michael P

AU - Gentry, Layne O.

AU - Rodriguez-Gomez, Guillermo

AU - Morowitz, William

AU - Polak, Elaine

AU - Rae, Jena K.

AU - Morgan, Nancy S.

AU - Williams, R. Rex

PY - 1998/2

Y1 - 1998/2

N2 - This prospective, multicenter randomized trial compared the safety and efficacy of 5-7 of therapy with oral levofloxacin (500 mg qd) with 7-10 days of therapy with cefaclor (250 mg tid) in the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB). One hundred ninety- two patients were evaluable of microbiologic efficacy. The overall bacteriologic eradication rates by pathogen were 94% and 87% for levoflaxacin and cefaclor, respectively. Levofloxacin eradicated 100% of Haemophilus influenzae, 95% of Moraxella catarrhalis, and 90% of Streptococcus pneumoniae organisms vs. 71%, 100%, and 86%, respectively, for cefaclor. Clinical success was observed in 92% of the patients in both groups. Drug-related adverse events were reported in 7% and 5% of patients, respectively, with gastrointestinal adverse events being the most common. These results indicate that once a day dosing of levofloxacin (500 mgg) is as effective and well tolerated as three-times-per-day dosing of cefaclor (250 mgg) in the treatment of patients with ABECB.

AB - This prospective, multicenter randomized trial compared the safety and efficacy of 5-7 of therapy with oral levofloxacin (500 mg qd) with 7-10 days of therapy with cefaclor (250 mg tid) in the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB). One hundred ninety- two patients were evaluable of microbiologic efficacy. The overall bacteriologic eradication rates by pathogen were 94% and 87% for levoflaxacin and cefaclor, respectively. Levofloxacin eradicated 100% of Haemophilus influenzae, 95% of Moraxella catarrhalis, and 90% of Streptococcus pneumoniae organisms vs. 71%, 100%, and 86%, respectively, for cefaclor. Clinical success was observed in 92% of the patients in both groups. Drug-related adverse events were reported in 7% and 5% of patients, respectively, with gastrointestinal adverse events being the most common. These results indicate that once a day dosing of levofloxacin (500 mgg) is as effective and well tolerated as three-times-per-day dosing of cefaclor (250 mgg) in the treatment of patients with ABECB.

UR - http://www.scopus.com/inward/record.url?scp=0031934272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031934272&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031934272

VL - 7

SP - 101

EP - 109

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 2

ER -